Vijeth S R, Dutta T K, Shahapurkar J, Sahai A
J Assoc Physicians India. 2000 Feb;48(2):187-91.
To assess the adequacy of initial standard dose of 100 ml of polyvalent anti-snake venom (ASV) and subsequent doses of 50 ml in correcting coagulation dysfunction in cases of viperine bite and to find the incidence of recurrence of coagulation dysfunction. The other objective was to correlate total requirement of ASV with initial coagulation profile.
Forty two adult patients of Echis carinatus bite with features of systemic envenomation, admitted over a period of 18 months, were monitored every six hours with bed-side clotting time (CT) and were given an initial standard dose of 100 ml of ASV intravenously. Further doses of 50 ml were administered six hourly until coagulation profile normalised or whenever a recurrence of coagulation dysfunction observed.
Twenty one (50%) of 42 patients who received initial standard dose of 100 ml of ASV required a subsequent 50 ml of ASV. Ten (23.8%) of them required a further 50 ml on subsequent test (making the total requirement at least 200 ml). Sixteen (72.7%) of 22 patients who had incoagulable blood at entry required further dose of anti-snake venom (after initial 100 ml), six required 150 ml and ten 200 ml or more before CT returned to normal. Recurrence of venom antigenemia as evidenced by prolonged clotting time was noticed in 15 patients (35.7%). The mean dose requirement of anti-snake venom was 179.2 ml.
Total requirement of anti-snake venom correlated positively with degree of coagulation dysfunction at entry. Hence patients having incoagulable blood at entry should be administered higher initial dose of ASV i.e., 150-200 ml. If needed as judged by CT, subsequent dose of ASV in patients having still incoagulable blood should be 100 ml (and those having mild dysfunction 50 ml) until total correction occurs Recurrence of coagulation dysfunction was observed in approximately one-third of patients and thus, CT should be monitored even after total correction.
评估初始标准剂量100毫升多价抗蛇毒血清(ASV)以及后续50毫升剂量在纠正蝰蛇咬伤病例凝血功能障碍方面的充足性,并找出凝血功能障碍复发的发生率。另一个目的是将抗蛇毒血清的总需求量与初始凝血指标相关联。
对42例有全身中毒症状的锯鳞蝰咬伤成年患者进行了为期18个月的观察,每6小时用床旁凝血时间(CT)进行监测,并静脉给予初始标准剂量100毫升抗蛇毒血清。此后每6小时给予50毫升剂量,直至凝血指标恢复正常或观察到凝血功能障碍复发。
42例接受初始标准剂量100毫升抗蛇毒血清的患者中,有21例(50%)需要后续50毫升抗蛇毒血清。其中10例(23.8%)在后续检测时还需要另外50毫升(使总需求量至少达到200毫升)。22例入院时血液无法凝固的患者中,有16例(72.7%)在初始100毫升抗蛇毒血清后需要进一步剂量,6例需要150毫升,10例需要200毫升或更多,直至凝血时间恢复正常。15例患者(35.7%)出现了凝血时间延长所证实的毒液抗原血症复发。抗蛇毒血清的平均需求量为179.2毫升。
抗蛇毒血清的总需求量与入院时凝血功能障碍的程度呈正相关。因此,入院时血液无法凝固的患者应给予更高的初始剂量抗蛇毒血清,即150 - 200毫升。根据凝血时间判断如有需要,血液仍无法凝固的患者后续抗蛇毒血清剂量应为100毫升(血液凝固功能轻度障碍的患者为50毫升),直至完全纠正。约三分之一的患者出现了凝血功能障碍复发,因此即使在完全纠正后仍应监测凝血时间。